Home Companies Catalysts Deep Dives
puxitatug samrotecan puxitatug samrotecan PHASE3
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Peak Sales Est$1500M
Formulations[]
Companies
AZN (ORIGINATOR)100%
Mechanism: HER3-directed (samrotecan payload)
Expert: Antibody-drug conjugate targeting HER3 with topoisomerase I inhibitor payload for HER3-expressing solid tumors.
Everyday: An antibody-drug combination targeting HER3 protein found on some cancers.
Targets: ["HER3"]
Programs (1)
IndicationStageKey StudyRegional Status
Solid (HER3+)PHASE1—[]
Notes
B7-H4 ADC for endometrial cancer.
Data from Supabase · Updated 2026-03-24